Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy for postmastectomy lymphangiosarcoma

B S Yap, H Y Yap, C M McBride

    Cancer
    |March 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Young smokers' interpretations of the estimated lung cancer risk associated with a common genetic variant of low penetrance.

    Public health genomics·2014
    Same author

    Effects of providing personalized feedback of child's obesity risk on mothers' food choices using a virtual reality buffet.

    International journal of obesity (2005)·2013
    Same author

    Skin cancer concerns and genetic risk information-seeking in primary care.

    Public health genomics·2011
    Same author

    Patient physical characteristics and primary care physician decision making in preconception genetic screening.

    Public health genomics·2009
    Same author

    Considerations for designing a prototype genetic test for use in translational research.

    Public health genomics·2009
    Same author

    What can interest tell us about uptake of genetic testing? Intention and behavior amongst smokers related to patients with lung cancer.

    Public health genomics·2009
    Same journal

    Toward exercise as standard care for older cancer survivors.

    Cancer·2026
    Same journal

    Maintenance therapy in gynecologic malignancies: Current and future state.

    Cancer·2026
    Same journal

    Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

    Cancer·2026
    Same journal

    Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

    Cancer·2026
    Same journal

    EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

    Cancer·2026
    Same journal

    Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

    Cancer·2026
    See all related articles

    Chemotherapy shows promise for treating rare postmastectomy lymphangiosarcoma. Patients responding to chemotherapy had significantly longer survival times compared to non-responders.

    Area of Science:

    • Oncology
    • Cancer Research

    Background:

    • Postmastectomy lymphangiosarcoma is a rare complication following breast cancer surgery.
    • Limited treatment options exist for this aggressive tumor.

    Purpose of the Study:

    • To evaluate the efficacy of chemotherapy in patients with postmastectomy lymphangiosarcoma.
    • To assess the impact of chemotherapy response on patient survival.

    Main Methods:

    • Retrospective analysis of 22 patients with postmastectomy lymphangiosarcoma treated over 20 years.
    • Review of chemotherapy regimens, including regional and systemic administration.
    • Assessment of treatment response and survival data.

    Main Results:

    • 13 patients received chemotherapy (regional, systemic, or both).

    Related Experiment Videos

  • Systemic chemotherapy achieved a 42% response rate (8/19), with responses seen with various agents.
  • Responders had a median survival of 26.5 months versus 4 months for non-responders.

    • Conclusions:

    • Chemotherapy, particularly systemic regimens, demonstrates significant activity against postmastectomy lymphangiosarcoma.
    • Chemotherapy response is associated with improved survival in these patients.
    • Chemotherapy should be considered a vital treatment modality for this rare tumor.